Drug updated on 3/28/2024
| Dosage Form | Injection (subcutaneous; 150mg/mL) |
| Drug Class | Interleukin-13 antagonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Summary
- Tralokinumab-ldrm (Adbry) is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
- A total of 12 systematic reviews/meta-analyses were reviewed to gather information about tralokinumab-ldrm (Adbry).
- When compared to dupilumab, tralokinumab showed lower odds of reaching EASI 50, indicating it might be less effective for certain endpoints such as achieving a 50% improvement in the Eczema Area and Severity Index.
- Against Janus Kinase Inhibitors like high-dose upadacitinib and abrocitinib, Adbry was found to be less effective; however, these drugs also presented a higher incidence of adverse events making tralokinumab a safer option albeit with potentially lower efficacy for some outcomes.
- Tralokinumab demonstrated significant effectiveness in improving AD symptoms such as Scoring Atopic Dermatitis score, achieving EASI -75%, and Investigator's Global Assessment scores within specified time frames.
- In terms of safety profile comparison against other drugs like Dupilimub and Janus Kinase inhibitors, tralokimumb (Abdry), alongside lebrikizmub were among the safest options showing only modest increase risk on conjunctivitis.
- The documents primarily focused on adult populations with moderate-to-severe atopic dermatitis without specific mention or detailed discussion on subgroups based demographics such as age (beyond "adults"), sex or ethnicity.
- A notable side effect associated specifically with Tralonkimuamb (Abdy) was an increased risk conjunctivits similar to other IL13 inhibitors but this elevated risk considered manageable compared broader adverse effects observed systemic treatments.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Adbry (tralokinumab-ldrm) Prescribing Information. | 2022 | LEO Pharma Inc., Madison, NJ |